Indeed, in these studies, the absolute beneficial effect of SGLT2 inhibitors on MACE outcomes and hospitalization for HF appears to be greatest in people with T2D and CKD (28, 36, 37). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.